aibio
Company Updates ·
Apimeds unit MindWave signs AssureChain deal with BlockAssure
MindWave will build, run and host an insurance network for BlockAssure and receive development fees plus 20% of the AssureCoin supply.
APUS Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US (APUS) news APUS reverse split, going concern, IPO and settlement news
Latest Apimeds Pharmaceuticals US news
- Company Updates
Apimeds names Eric Sherb chief financial officer
Erick Frim resigned as interim chief financial officer on September 29, 2026, and the board appointed Eric Sherb effective October 1, 2026, at a base salary of $60,000 a year.
- Company Updates
Apimeds Pharmaceuticals adds Sungjoon Chae to board
The appointment on September 10, 2026 followed a First Amendment to a settlement agreement that sets the board's interim makeup. Chae has been Co-Chief Executive Officer since May 4, 2026.
- Company Updates
Apimeds Pharmaceuticals takes assignment of Apitox rights
Under an agreement dated August 19, 2026, FreeT Inc. assigned to Apimeds Pharmaceuticals a set of Apitox rights, including 100% of the Korean medicine clinic market and a 25% royalty entitlement on U.S. proceeds.
- Listings
Apimeds Pharmaceuticals reverse stock split took effect July 24
The one-for-ten split took effect on July 24, 2026, and the stock trades on NYSE American under APUS on a split-adjusted basis, with par value cut to $0.001.
- Listings
Apimeds Pharmaceuticals sets reverse split date of July 24
The company said on July 13, 2026 that its one-for-ten reverse split would take effect on July 24, after a March 2026 target passed without a filing.
- Distress
Apimeds Pharmaceuticals US files NT 10-Q, says quarterly report for March 31, 2026 will be late
Apimeds (APUS) says it needs more time to finalize financial statements for the quarter ended March 31, 2026 and expects to file within a five-calendar-day extension. Its latest 10-K carries a going concern paragraph.
- Company Updates
Apimeds Pharmaceuticals appoints Sungjoon Chae co-chief executive
Apimeds named Sungjoon Chae Co-Chief Executive Officer on May 4, 2026 on a stockholder's nomination. The Form 8-K, dated May 5, 2026, describes his background as an architect and urban designer.
- Listings
Apimeds Pharmaceuticals gets NYSE American late filing notice for 2025 Form 10-K
NYSE Regulation told Apimeds Pharmaceuticals US on April 17, 2026 that it had not filed its 2025 annual report on time. The company has until October 15, 2026 to file, its stock carries a ".LF" tag, and a trading halt that began April 2 is still in effect.
- Distress
Apimeds Pharmaceuticals delays quarterly report for period ended June 30, 2025
Apimeds says it cannot file its quarterly report for the period ended June 30, 2025 on time and expects to file within the five-day extension. Its lead drug, Apitox, rests on a prior Phase III trial that the company's own filing describes in conflicting terms.
- Financings
Apimeds Pharmaceuticals US prices $13.5 million IPO at $4.00 a share
Apimeds is selling 3,375,000 shares at $4.00 for $13.5 million gross and listing on the NYSE American as APUS. Its controlling holder stays above 54%, and the company carries a going-concern paragraph from its auditor.
What Apimeds Pharmaceuticals US does
Apimeds Pharmaceuticals US, Inc. is a Delaware corporation that closed a merger on December 1, 2025, in which MindWave Innovations Inc. became a wholly owned subsidiary. The company conducts its business through two wholly owned operating subsidiaries, Lokahi Therapeutics, Inc. and MindWave Innovations Inc. Lokahi is a clinical stage biopharmaceutical company developing Apitox, an intradermally administered bee venom-based toxin, with its focus on inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is a purified, pharmaceutical grade venom from the western honeybee, which the FDA classifies as an active pharmaceutical ingredient. Apimeds Inc. markets and sells the product in South Korea as Apitoxin for the treatment of OA, but the company says it is not associated with those sales and that Apitoxin has not yet been approved by the FDA for any indication. The company also describes a 1-for-10 reverse stock split and a change in control tied to a new NYSE American listing application.
| Product or program | What it is | Stage |
|---|---|---|
| Apitox | Intradermal bee venom-based toxin for inflammation and pain in knee OA and MS | Clinical stage |
| Apitoxin | Bee venom product marketed for OA in South Korea by Apimeds Inc. | Marketed in South Korea; not approved by the FDA |
Apimeds Pharmaceuticals US annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $1.6 million | |
| Net income (loss) | -$6.0 million | -$1.4 million |
| Cash from operations | -$8.9 million | -$733,526 |
| Cash and equivalents | $1.6 million | $3,455 |
| Short-term investments | $2.0 million |
Questions about Apimeds Pharmaceuticals US
Did Apimeds Pharmaceuticals US do a reverse stock split?
Our latest story on this, dated Jul 24, 2026: "Apimeds Pharmaceuticals reverse stock split took effect July 24". The story links the filing or release it is based on. Read the story.
Has Apimeds Pharmaceuticals US issued a going-concern warning?
Our latest story on this, dated May 15, 2026: "Apimeds Pharmaceuticals US files NT 10-Q, says quarterly report for March 31, 2026 will be late". The story links the filing or release it is based on. Read the story.
When did Apimeds Pharmaceuticals US go public?
Our latest story on this, dated May 9, 2025: "Apimeds Pharmaceuticals US prices $13.5 million IPO at $4.00 a share". The story links the filing or release it is based on. Read the story.
Has Apimeds Pharmaceuticals US settled a lawsuit?
Our latest story on this, dated Sep 10, 2026: "Apimeds Pharmaceuticals adds Sungjoon Chae to board". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Apimeds Pharmaceuticals US?
Apimeds Pharmaceuticals US, Inc. trades under the ticker APUS on AMEX.
Where is Apimeds Pharmaceuticals US listed?
Apimeds Pharmaceuticals US, Inc. is listed on AMEX.
What is the SEC CIK of Apimeds Pharmaceuticals US?
The SEC Central Index Key (CIK) for Apimeds Pharmaceuticals US, Inc. is 1894525. Its filings are on SEC EDGAR.
How many shares does Apimeds Pharmaceuticals US have outstanding?
1,509,118 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-14.
Which country or territory is Apimeds Pharmaceuticals US listed under?
Our directory records Apimeds Pharmaceuticals US, Inc. under United States.
What does Apimeds Pharmaceuticals US do?
Our directory classifies Apimeds Pharmaceuticals US, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Apimeds Pharmaceuticals US?
The ISIN recorded for Apimeds Pharmaceuticals US, Inc. is US03771D2018.
Does aibio.space cover Apimeds Pharmaceuticals US?
aibio.space lists Apimeds Pharmaceuticals US, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Apimeds Pharmaceuticals US incorporated?
SEC records list its state or country of incorporation as DE.
What does Apimeds Pharmaceuticals US develop?
Apimeds Pharmaceuticals US, Inc. is a Delaware corporation that closed a merger on December 1, 2025, in which MindWave Innovations Inc. became a wholly owned subsidiary. The company conducts its business through two wholly owned operating subsidiaries, Lokahi Therapeutics, Inc. and MindWave Innovations Inc. Lokahi is a clinical stage biopharmaceutical company developing Apitox, an intradermally administered bee venom-based toxin, with its focus on inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS.
What is Apitox from Apimeds Pharmaceuticals US?
Apitox: Intradermal bee venom-based toxin for inflammation and pain in knee OA and MS Stage: Clinical stage.
Investor discussion: Apimeds Pharmaceuticals US
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
- Mergers
Reported a merger or acquisition agreement. SEC Form 425. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 8.01). Source
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,2.03,3.02,5.01,5.02,5.03,7.01,9.01). Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
- Financings
Reported a financing. SEC Form 424B4. Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Stock chart
SEC filings and registration
- SEC name
- Apimeds Pharmaceuticals US, Inc.
- CIK
- 1894525
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- APUS (NYSE)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- <br>Emerging growth company
- Business address
- 100 MATAWAN RD, MATAWAN, NJ, 07747
- Phone
- 848-201-5010
- Shares outstanding
- 1,509,118 as of 2026-08-12 (10-Q filed 2026-08-14)
Recent filings
Listing details
- Company
- Apimeds Pharmaceuticals US, Inc.
- Ticker
- APUS
- Listing
- AMEX
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US03771D2018
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction